Gilead Sciences is buying cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion. AP
Gilead Sciences is buying cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion. AP

Gilead acquires Forty Seven for $4.9bn as it eyes expansion into cancer treatment